Safety and Efficacy of Dose Conversion From Vicodin® to Buprenorphine Transdermal System (Butrans™) in Subjects With OA Pain
A Randomized, Double-Blind Study Evaluating the Dose Conversion From Vicodin® to Buprenorphine Transdermal System (BTDS) in Subjects With Osteoarthritis (OA) Pain
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Detailed Description
Study Type
Study Type
Enrollment (Actual)
Enrollment
Phase
Phase
- Phase 3
Contacts and Locations
Study Locations
-
-
Alabama
-
Birmingham, Alabama, United States, 35007
- Southern Drug Research
-
-
Arizona
-
Phoenix, Arizona, United States, 85029
- Redpoint Research
-
Tucson, Arizona, United States, 85712
- Advanced Clinical Therapeutics
-
Tucson, Arizona, United States, 85712
- Tucson Orthopedic Institute
-
-
Arkansas
-
Hot Springs, Arkansas, United States, 71913
- Hot Springs Mercy Pain Clinic
-
Pine Bluff, Arkansas, United States, 71603
- Private practice
-
-
California
-
Anaheim, California, United States, 92801
- Advanced Clinical Research Institute
-
Beverly Hills, California, United States, 90211
- Lovelace Scientific Resources
-
Buena Park, California, United States, 90620
- Southbay Pharma Research
-
Clovis, California, United States, 93611
- Community Medical Providers
-
Escondido, California, United States, 92025
- Kaiser Permanente
-
Santa Monica, California, United States, 90404
- Univ. of Southern California
-
-
Connecticut
-
Waterbury, Connecticut, United States, 06708
- Arthritis Center of CT
-
-
Florida
-
Miami, Florida, United States, 33186
- Lifespan Research Foundation, Inc.
-
Miami Beach, Florida, United States, 33140
- Miami Beach Anesthesiology Associates
-
Naples, Florida, United States, 34102
- Neuro Science and Spine Assoc.
-
Tamarac, Florida, United States, 33321
- West Broward Rheumatology Association, Inc.
-
-
Idaho
-
Boise, Idaho, United States, 83702
- Intermountain Orthopaedics
-
-
Kansas
-
Kansas City, Kansas, United States, 66160
- University of Kansas Medical Center
-
-
Kentucky
-
Lexington, Kentucky, United States, 40509
- Bluegrass Orthopaedics
-
Madisonville, Kentucky, United States, 42431
- Commonwealth Biomedical Research, LLC
-
-
Louisiana
-
New Orleans, Louisiana, United States, 70128
- Dolby Providers, Inc.
-
-
Massachusetts
-
Worcester, Massachusetts, United States, 01610
- Clinical Pharmacology Study Group
-
-
Michigan
-
Kalamazoo, Michigan, United States, 49009
- Westside Family Medical Center
-
Lansing, Michigan, United States, 48917
- PCM Medical Services
-
-
Missouri
-
St. Louis, Missouri, United States, 63141
- HealthCare Research LLC
-
-
New Hampshire
-
Barrington, New Hampshire, United States, 03825
- Northeast Pain Research Center
-
-
North Carolina
-
Charlotte, North Carolina, United States, 28210
- The Arthritis Clinic and Carolina Bone and Joint
-
-
Ohio
-
Dayton, Ohio, United States, 45402
- Dayton Primary and Urgent Care
-
-
Oregon
-
Medford, Oregon, United States, 97504
- The Medford Medical Clinic
-
-
South Carolina
-
Orangeburg, South Carolina, United States, 29118
- The Arthritis and Osteoporosis Center
-
-
Texas
-
Austin, Texas, United States, 78759
- CEDRA Clinical Research,
-
Dallas, Texas, United States, 75235
- Renaissance Clinical Research & Hypertension Clinic
-
Houston, Texas, United States, 77074
- Spine Care Southwest.
-
Richardson, Texas, United States, 75080
- KRK Medical Research
-
-
Wisconsin
-
Monroe, Wisconsin, United States, 53566
- Monroe Medical Foundation
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- osteoarthritis of the hip or knee taking a regularly scheduled regimen of hydrocodone/ acetaminophen for their osteoarthritis OA pain.
Exclusion Criteria:
- currently have condition requiring a stable regimen of acetaminophen (APAP).
- a history of chronic conditions, other than OA of the hip or knee joints, requiring frequent, intermittent analgesic therapy.
Other protocol-specific exclusion/inclusion criteria may apply.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: TREATMENT
- Allocation: RANDOMIZED
- Interventional Model: PARALLEL
- Masking: DOUBLE
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
EXPERIMENTAL: BTDS10/20
Initial doses (Level 1) of BTDS 10.
Subjects were allowed to have their doses adjusted to BTDS 20 (Level 2) on or after day 4.
|
Buprenorphine transdermal patch applied for 7-day wear.
Other Names:
|
|
EXPERIMENTAL: BTDS 20
Initial doses (Level 1) of BTDS 20.
|
Buprenorphine transdermal patch applied for 7-day wear.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
The Percentage of Subjects Who Completed the 14-day Double-blind Phase.
Time Frame: 14 days
|
The indicator variable was 1 = completion, and 0 = noncompletion.
For the primary efficacy analysis, the percentage of subjects who completed the double-blind phase was computed with its 95% confidence interval (CI) for each treatment regimen (starting dose of BTDS 10 or BTDS 20) across and within baseline Vicodin® stratum (15 to 22.5mg/day vs >22.5 to 30 mg/day as determined by the daily average hydrocodone dose during the run-in period).
|
14 days
|
Collaborators and Investigators
Sponsor
Sponsor
Publications and helpful links
Helpful Links
Study record dates
Study Major Dates
Study Start
Study Start
Primary Completion (ACTUAL)
Primary Completion
Study Completion (ACTUAL)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (ESTIMATE)
First Posted
Study Record Updates
Last Update Posted (ESTIMATE)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- BUP3018
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.